Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

The forward yield is currently 4.8%, while the company has raised its payouts by 90% in the past 10 years. It might be facing ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...